GRANULES: Revenue rose 20% as complex generics grew and net cash reached ₹8,280 Mn

What happened

Granules reported Q2 FY27 revenue up 20% year over year and profit after tax up 39%. Gross margin eased as input and logistics costs rose. Warrant proceeds raised net cash to ₹8,280 Mn, while the company continued investment in complex generics, research and development, and manufacturing.

Confirmed

Global impact / market context

Higher sales and profit indicate growth, but rising input and shipping costs reduced the share of revenue left after direct production costs. The warrant proceeds provide cash for ongoing research, complex generic medicines, and manufacturing, potentially supporting future output while costs remain a constraint.

Analyst inference

The reported figures reflect both business performance and financing: revenue and profit rose, while warrant proceeds increased net cash. Investors may distinguish funds raised from funds earned through sales, then consider whether spending on complex generics and manufacturing can support growth despite higher input and logistics costs and a lower gross margin.

Analyst inference

What to watch

1. Track upcoming revenue and profit reports to see whether the 20% sales growth and 39% profit growth continue, and whether gross margin stabilizes as costs change. Analyst inference
2. Look for updates on complex generics, research spending, and manufacturing investment; the article says these investments continued but gives no project timelines or expected returns. Confirmed
3. Watch whether net cash changes after the warrant proceeds and continued investment, since spending on research and manufacturing can reduce cash available if operating inflows do not keep pace. Analyst inference

Evidence

• Original source link unavailable